Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Payment Caps For Part B Drugs With Accelerated Approvals Endorsed By MedPAC

Executive Summary

Recommendation meant to drive completion of confirmatory trials for accelerated approvals will be forwarded to Congress. Medicare Payment Advisory Commission also recommends allowing Part B to use reference pricing and to adjust ASP payment add-ons for providers.

You may also be interested in...



An Elegy For Aduhelm

Biogen’s decision to discontinue is Alzheimer’s treatment Aduhelm cements its status as one of the most spectacular commercial failures in biopharma history. But its impact on biopharma policy is still extraordinary.

Biosimilars in Medicare Part B: CMS Weighing Payment Demonstration To Boost Uptake

Agency cites possible demonstration in response to HHS Office of Inspector General report urging reimbursement reforms to spur greater use of biosimilars and lower costs for Medicare and beneficiaries.

Biosimilars in Medicare Part B: CMS Weighing Payment Demonstration To Boost Uptake

Agency cites possible demonstration in response to HHS Office of Inspector General report urging reimbursement reforms to spur greater use of biosimilars and lower costs for Medicare and beneficiaries.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS148048

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel